NSABP Objects to “Closed Process” For Review Of P-4 Breast Cancer Chemoprevention Trial.
NCI Barred PI Wolmark And Its Own Prevention Staff From Ad Hod Meeting.
NCI Director To Decide Fate Of P-4 After NCAB Meeting In June.
Paul Goss, Patricia Ganz Discuss Breast Cancer Prevention Trials.
Aranesp Study Finds No Difference In Survival Or Progression In Small-Cell Lung Cancer.
Trending Stories
- As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded - Proposed OMB rule aims at the heart of the U.S. research enterprise—and scientists are fighting back
“The question isn’t whether politics will influence research. Under this proposal, that’s the point. That’s their goal.” - Pancreatic cancer breakthrough came from smart scientists making smart bets—not from politicization of science
- House bill gives NCI $7.4 billion in FY 2027—$110 million above current budget
- NIH calls for comment on proposal to limit the number of RPGs per PI
- Lessons from the AIDS Quilt: what the cancer world can learn from AIDS advocacy









